Tag Archives: Ken Kaitin
By William Looney | Published: July 23, 2013
With a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. Dr. Wang Chenguang, Dean of Tsinghua Law School Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a sobering [...]
By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?